Payment overview · 2025
General Payments
$62.25
3 reported records · 2 companies
Healthcare provider profile · identity verified
Robert J Davidson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PINCKNEYVILLE, IL · NPI 1790774826
Verified facts
What the public records show
CMS Open Payments records show Robert J Davidson, M.D. received $62.25 in general payments during 2025 across 3 reported records.
Novo Nordisk Inc accounted for 74.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.11 | 74.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.14 | 25.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $62.25 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.11 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.11 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 625 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 112 |
| Potassium Chloride | Potassium Chloride | 519 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 515 | 84 |
| Furosemide | Furosemide | 511 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 334 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 313 | 80 |
| Lorazepam | Lorazepam | 289 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 271 | 57 |
| Omeprazole | Omeprazole | 265 | 66 |
| Gabapentin | Gabapentin | 262 | 55 |
| Lisinopril | Lisinopril | 258 | 62 |
| Citalopram Hbr | Citalopram Hydrobromide | 233 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 225 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 224 | 49 |
| Sertraline Hcl | Sertraline Hcl | 210 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 39 |
| Donepezil Hcl | Donepezil Hcl | 196 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 45 |
| Losartan Potassium | Losartan Potassium | 176 | 33 |
| Trazodone Hcl | Trazodone Hcl | 164 | 28 |
| Mirtazapine | Mirtazapine | 149 | 26 |
| Levetiracetam | Levetiracetam | 147 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 145 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 140 | 29 |
| Metformin Hcl | Metformin Hcl | 132 | 26 |
| Famotidine | Famotidine | 128 | 23 |
| Tramadol Hcl | Tramadol Hcl | 125 | 35 |
| Memantine Hcl | Memantine Hcl | 124 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 36 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 113 | 110 |
| Carvedilol | Carvedilol | 110 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 93 | 14 |
| Xarelto | Rivaroxaban | 89 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 87 | 18 |
| Cephalexin | Cephalexin | 85 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 14 |
| Meloxicam | Meloxicam | 81 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 14 |
| Risperidone | Risperidone | 77 | 15 |
| Spironolactone | Spironolactone | 77 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 14 |
| Alprazolam | Alprazolam | 75 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 41 |
| Silver Sulfadiazine | Silver Sulfadiazine | 74 | 28 |
| Jardiance | Empagliflozin | 73 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | suppressed |
| Allopurinol | Allopurinol | 70 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 21 |
| Permethrin | Permethrin | 69 | 49 |
| Finasteride | Finasteride | 68 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 68 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 52 |
| Olanzapine | Olanzapine | 67 | 11 |
| Warfarin Sodium | Warfarin Sodium | 67 | suppressed |
| Aripiprazole | Aripiprazole | 66 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | suppressed |
| Myrbetriq | Mirabegron | 62 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 61 | 11 |
| Nystatin | Nystatin | 61 | 13 |
| Glipizide | Glipizide | 60 | 15 |
| Simvastatin | Simvastatin | 59 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | suppressed |
| Pregabalin | Pregabalin | 57 | 11 |
| Alendronate Sodium | Alendronate Sodium | 56 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 56 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 34 |
| Farxiga | Dapagliflozin Propanediol | 55 | suppressed |
| Atenolol | Atenolol | 54 | 12 |
| Prednisone | Prednisone | 54 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 50 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 50 | suppressed |
| Clonazepam | Clonazepam | 49 | suppressed |
| Ibuprofen | Ibuprofen | 49 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | suppressed |
| Haloperidol | Haloperidol | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 19 |
| Bumetanide | Bumetanide | 41 | suppressed |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Lacosamide | Lacosamide | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 17 |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 33 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 32 | 19 |
| Amoxicillin | Amoxicillin | 30 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | 14 |
| Linzess | Linaclotide | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 22 | suppressed |
| Humalog | Insulin Lispro | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Nyamyc | Nystatin | 20 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 15 |
| Imipramine Hcl | Imipramine Hcl | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | suppressed |
| Entacapone | Entacapone | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Olanzapine Odt | Olanzapine | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | 11 |
| Estradiol | Estradiol | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | 11 |
| Nitroglycerin | Nitroglycerin | 11 | 11 |
| Novolog | Insulin Aspart | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $62.25 · 3 records | Novo Nordisk Inc | BREZTRI, Ozempic, Rybelsus | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error